EGFR and non-small cell lung carcinoma: In an earlier scenario, the randomized NORTHSTAR trial (NCT03410043) will evaluate if the combination of SABR plus osimertinib is better than osimetinib alone in stage IIIB/IV EGFR+ NSCLC as first-line therapy.